Copyright: ©Author(s) 2026.
World J Gastroenterol. Aug 28, 2026; 32(32): 118570
Published online Aug 28, 2026. doi: 10.3748/wjg.118570
Published online Aug 28, 2026. doi: 10.3748/wjg.118570
Table 2 Tumour characteristics and stereotactic body radiotherapy parameters (n = 60 treatment courses), n (%)/interquartile range
| Variable | n = 60 |
| BCLC stage | |
| Stage 0 | 10 (16.67) |
| Stage A | 16 (26.67) |
| Stage B | 24 (40.00) |
| Stage C | 10 (16.67) |
| Vascular invasion | 6 (10.00) |
| Reason for SBRT | |
| First-line curative ablation | 2 (3.33) |
| Salvage curative ablation | 13 (21.67) |
| Bridge to liver transplant | 13 (21.67) |
| Alternative to TACE/SIRT/sorafenib | 7 (11.67) |
| In combination with TACE | 15 (25.00) |
| Non-ablative treatment of recurrence after prior locoregional therapies | 10 (16.67) |
| Prior HCC treatment | |
| TACE | 51 (85.00) |
| RFA/microwave | 18 (30.00) |
| Resection | 2 (3.33) |
| SIRT | 2 (3.33) |
| Percutaneous ethanol injection | 2 (3.33) |
| No prior treatment | 6 (10.00) |
| Motion management | |
| Exhale breath-hold | 32 (53.33) |
| Inhale breath-hold | 18 (30) |
| Free breathing | 10 (16.67) |
| Dose fractionation | |
| 40 Gy in 5 fractions | 27 (45.00) |
| 30 Gy in 5 fractions | 10 (16.70) |
| 50 Gy in 5 fractions | 5 (8.30) |
| 40 Gy in 6 fractions | 4 (6.45) |
| 35 Gy in 5 fractions | 4 (6.45) |
| Other schedules | 10 (16.70) |
| Median BED10 prescription dose (Gy) | 72 (53.25-72.00) |
| Maximum tumour diameter (mm) | 24.5 (18-35) |
| GTV volume (cc) | 4.83 (2.87-14.73) |
| PTV volume (cc) | 21.82 (14.66-48.91) |
| PTV D95 (Gy) | |
| First lesion | 66.3 (49.00-73.40) |
| Second lesion (n = 4) | 67.60 (58.96-72.82) |
| PTV Dmin | |
| First lesion | 61.42 (45.93-71.33) |
| Second lesion (n = 4) | 68.47 (57.97-73.07) |
| PTV Dmax | |
| First lesion | 106.19 (76.21-112.58) |
| Second lesion (n = 4) | 113.72 (109.67-130.09) |
| Liver-GTV (cc) | 1560.9 (1156.80-2015.20) |
| Mean dose to liver-GTV (Gy) | 4.56 (3.06-6.33) |
| Liver-GTV volume (cc) < 15 Gy | 1146 (944-1431) |
| OAR limiting dose | |
| Liver | 9 (15.00) |
| Stomach/oesophagus | 3 (5.00) |
| Small bowel | 1(1.67) |
| Large bowel | 1 (1.67) |
| Central bile ducts | 9 (15.00) |
| Heart | 7 (11.67) |
| Other (chest wall, IVC and duodenum) | 10 (16.67) |
| Patient completed prescribed course | 59 (98.33) |
- Citation: Fong SC, Ng SP, Italiano D, Chung W, Vaz K, Fink M, Goodwin M, Ranatunga D, Khor R. Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre. World J Gastroenterol 2026; 32(32): 118570
- URL: https://www.wjgnet.com/1007-9327/full/v32/i32/118570.htm
- DOI: https://dx.doi.org/10.3748/wjg.118570